(15352506), C. A., (15352509), A. B., (15352512), R. S., (15352515), M. G., (15352518), A. C., (15086287), D. R., . . . (15352566), C. C. (2025). Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Citación estilo Chicago(15352506), Carlotta Antoniotti, et al. Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.
Cita MLA(15352506), Carlotta Antoniotti, et al. Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.